Teva Wins Ratiopharm For $5 Billion, And Gains A Key Foothold In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
The acquisition makes Teva the leading generics company in Europe, which is a key to its ambitious plans for global growth.